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Abstract
The mammalian two-hybrid system MAPPIT allows the detection of protein-protein interactions in intact human cells. We
developed a random mutagenesis screening strategy based on MAPPIT to detect mutations that disrupt the interaction of
one protein with multiple protein interactors simultanously. The strategy was used to detect residues of the human cytidine
deaminase Apobec3G that are important for its homodimerization and its interaction with the HIV-1 Gag and Vif proteins.
The strategy is able to identify the previously described head-to-head homodimerization interface in the N-terminal domain
of Apobec3G. Our analysis further detects two new potential interaction surfaces in the N-and C-terminal domain of
Apobec3G for interaction with Vif and Gag or for Apobec3G dimerization.
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Introduction
To reveal how proteins interact in a protein complex, the
detailed structure of the complex is ideally determined via
crystallography methods or NMR. However, the structure
determination of protein complexes remains challenging and the
number of complex structures lags far behind the number of
known protein interactions [1]. This gap will grow as inter-
actomics projects lead to a vast increase in the number of known
protein-protein interactions. Alternative methods are developed
for prediction of protein complex structures to -at least partially-
bridge this gap. In silico methods such as homology based
modeling and protein-protein docking can predict the structure of
protein complexes [124]. Additionally, fitting of monomer
structures or models into low resolution structures of the complex
obtained via SAXS, cryo-electron microscopy or electron tomog-
raphy can provide a model for the complex [527]. Models from
these predictions can further be validated by experimental
methods, such as mutagenesis of the predicted interface(s)
combined with a method to detect the specific protein-protein
interaction. Conversely, experimental identification of interface
residues can help to guide the docking process in data-driven
docking, often resulting in better models [8]. The development of
new methods to determine interfaces in protein-protein interac-
tions can thus contribute to the development of alternative
methods for complex structure modeling. We here propose a new
random mutagenesis strategy to identify putative interface residues
based on the mammalian two-hybrid method MAPPIT.
MAPPIT is a two-hybrid method based on reconstitution of
cytokine receptor signaling for the detection of protein-protein
interactions [9]. The MAPPIT principle is outlined in figure S1 in
supporting information. We previously used MAPPIT and site
directed mutagenesis to identify an interface in the human host
restriction factor Apobec3G that is important for its dimerization
and its interaction with the HIV-1 protein Vif [10]. Human
apolipoprotein B messenger RNA-editing catalytic polypeptide-
like G (Apobec3G) is a member of the Apobec protein family of
cytidine deaminases [11]. Apobec3G is a host restriction factor
that inhibits the infectivity of HIV-1 virus particles that lack the
accessory protein virion infectivity factor (Vif) [12]. Apobec3G is
incorporated into newly formed HIV-1 virions and catalyzes
cytidine deamination during reverse transcription of the viral
genome in infected cells. This leads to hypermutation and
degradation of the newly synthesized viral DNA [13216].
Apobec3G further restricts HIV-1 infection through deaminase-
independent mechanisms [17226]. Unfortunately, HIV-1 can
efficiently counteract the restrictive effects of Apobec3G by Vif.
HIV-1 Vif is a 23 kDa protein that targets Apobec3G for
proteasomal degradation [27231]. Vif binds to Apobec3G and
recruits via its SOCS box domain an E3 ubiquitin ligase complex
with Cullin-5, Elongin B, Elongin C and Rbx1 subunits [32,33].
This leads to the ubiquitination of Apobec3G and degradation by
the 26S proteasome.
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Apobec3G contains two characteristic cytidine deaminase
(CDA) domains [34]. Only the C-terminal CDA domain (CD2)
is catalytically active in cytidine deamination, whereas the N-
terminal CDA domain (CD1) is involved in nucleic acid binding
and virion incorporation [19,35237]. Virion incorporation of
Apobec3G is mediated via the RNA-dependent interaction with
the conserved nucleocapsid domain of the HIV-1 Gag protein.
The nucleocapsid domain is necessary and sufficient for interac-
tion with and incorporation of Apobec3G in virus-like particles
[38243]. The structure of the CD2 domain of Apobec3G has
been determined by X-ray crystallography and NMR [44248].
This Apobec3G domain folds into a five-stranded b sheet flanked
by six a helices. Several homology models have been proposed for
the CD1 domain [10,47252]. In the crystal structure of the
related Apobec2, its single deaminase domain forms tetramers via
two types of interactions: two domains interact symmetrically by
pairing of their b2 strands. Two dimers further form tetramers via
a symmetrical head-to-head interface containing residues of the
a1-b1 and b4-a4 loops and the a6 helix [53]. A similar head-to-
head interface was proposed and identified for the N-terminal
domain of Apobec3G [10,51,52]. Mutations in this interface affect
multiple aspects of Apobec3G function including dimerization,
virion incorporation, cellular localization and interaction with Vif
[10,51,52]. Using MAPPIT, homology modeling and site directed
mutagenesis we mapped residues in this dimerization interface in
CD1 of Apobec3G that are important for the Apobec3G-
Apobec3G interactions [10].
Here, we tested the effect of mutations in the dimerization
interface on the interaction between Apobec3G and Gag. We
present a new strategy to screen for mutations that disrupt a
protein-protein interaction based on random mutagenesis in
combination with MAPPIT. The strategy allows evaluating the
effect of many random mutations in one protein on interaction
with multiple interaction partners in parallel. Using this strategy,
we identified regions in both Apobec3G domains that are involved
in the interaction of Apobec3G with Apobec3G, Vif and Gag.
Results
MAPPIT-analysis of the Apobec3G-Gag interaction
reveals a similar interaction pattern as Apobec3G
homomerization
We previously used MAPPIT to demonstrate the importance of
the head-to-head interface of the Apobec3G N-terminal domain
for the Apobec3G-Apobec3G and the Apobec3G-Vif interaction
[10]. Here, we used MAPPIT to study the role of this interface in
the Apobec3G-Gag interaction.
MAPPIT allowed the detection of the interaction of the
Apobec3G bait with Gagpol and Gag, which originates from the
Gagpol precursor polyprotein, coupled as prey. The Gagpol prey
led to a robust MAPPIT signal, while the Gag prey resulted in a
modest but reproducible MAPPIT signal (Figure 1A and 2). A
MAPPIT prey with a truncated Gag (amino acids 12377) misses
the Gag nucleocapsid domain and showed no MAPPIT signal
(figure S2). This is in line with the important role of the
nucleocapsid domain in the Apobec3G-Gag interaction
[38243]. In our previous study, a panel of Apobec3G bait
mutants in the head-to-head interface of the N-terminal domain
was generated. We tested the association of these Apobec3G
mutants with the Gagpol prey and confirmed the data with the
Gag prey. The effect of Apobec3G bait mutations on the
interaction with Gagpol or Gag is quasi identical to their effect
on the interaction with Apobec3G (Table 1 and Figure 1B and 1C)
[10]. This observation indicates that mutations that disrupt the
head-to-head interaction of Apobec3G N-terminal domains also
disrupt the interaction with Gag. The RNA-mediated head-to-
head interaction of two Apobec3Gs may be required for Gag
binding.
We showed before that four mutations at the edge of the head-
to-head interface specifically affected the Apobec3G-Vif interac-
tion: D128K and P129A disturbed the interaction with Vif
whereas a T32Q and a K99D mutation increased the MAPPIT
signal [10]. These mutations do not affect the Apobec3G-Gag
interaction, which shows that the mutated residues are specifically
involved in the interaction with Vif.
Both N- and C-terminal domains of Apobec3G are
involved in the interactions of Apobec3G with
Apobec3G, Vif and Gag
To investigate the role of the N- and C-terminal domains of
Apobec3G in the interaction with Apobec3G, Vif and Gag, the N-
and C-terminal domains of Apobec3G were coupled as MAPPIT
baits. The interaction of these baits with four different MAPPIT
preys containing respectively codon optimized Vif SLQ144-
146AAA, wild type Apobec3G, Gagpol and SH2-Bb, was tested.
The SLQ144-146AAA mutation in the Vif prey prevents
proteasomal degradation of the Apobec3G bait, and results in a
higher MAPPIT signal [32]. We will further refer to this prey as
the ‘Vif prey’. The SH2-Bb prey is used as a positive control to test
the expression of the bait mutants. SH2-Bb interacts with JAK2
bound to the bait receptor [54] and the SH2-Bb prey therefore
gives a positive MAPPIT signal with any MAPPIT bait that is
expressed at the plasma membrane. The pMG2-SVT prey is used
as a negative control in our experiments.
While most reports show the interaction of Vif with the
Apobec3G CD1 domain [37,55,56], our assay demonstrates that
Vif may also be able to interact with the C-terminal domain of
Apobec3G (Figure 2A). However, the MAPPIT signal is much
more robust with the full-length Apobec3G bait. The isolated N-
or C-terminal Apobec3G domains do not interact with Gag
(Figure 2B). We could not show interaction between the full-length
Apobec3G prey and the isolated N-terminal or C-terminal domain
of Apobec3G as bait (Figure 2A). This suggests that the head-to-
head interaction between the N-terminal domains is promoted by
the presence of the C-terminal domain. Based on these data, we
propose that the N- and C-terminal domains both play a role in
Apobec3G dimerization or oligomerization and in the interaction
with Vif and Gag. We therefore further identified the exact
binding sites in both domains as described below.
Development of a random mutagenesis MAPPIT strategy
and its application for analysis of the Apobec3G –
Apobec3G, Apobec3G-Vif and Apobec3G-Gag
interactions
Our mapping of binding sites in Apobec3G via mutagenesis was
hitherto restricted to the predicted head-to-head interface in the
N-terminal domain of Apobec3G. To extend this mapping to the
entire Apobec3G protein, we developed a method to screen for
mutations that disrupt protein-protein interactions via a combi-
nation of random mutagenesis and MAPPIT. In this method, we
randomly mutate the MAPPIT bait insert via error prone PCR
and test the interaction of the different mutants with several preys
by co-transfection of HEK293T cells in 384-well format (Figure 3).
To screen for mutations in Apobec3G that decrease the
interaction with Apobec3G, Vif or Gag, two slightly overlapping
fragments of Apobec3G (amino acids 1 to 178 and amino acids
175 to 384) were mutated separately. 1152 potential bait mutants
Random Mutagenesis MAPPIT of Apobec3G
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from each mutagenesis were isolated. The interaction of these
2304 potential bait mutants with four different MAPPIT preys
containing respectively codon optimized Vif SLQ144-146AAA,
wild type Apobec3G, Gagpol and SH2-Bb, was tested.
In a proof of principle experiment, the capability of the strategy
to distinguish between the interaction of the Vif prey with the wild
type and the W127A mutated Apobec3G MAPPIT bait, was
examined. As shown in figure 4A, the method clearly allows
discriminating between the wild type and the mutant colonies.
In the random mutagenesis MAPPIT screen, each transfection
was performed in triplicate and the relative MAPPIT signal of the
mutants compared to six control wild types was calculated as
described in the materials and methods section. To estimate the
variation of the relative MAPPIT signal for wild type Apobec3G,
every wild type control was compared first with the median of the
five other wild type controls on the plate. In this analysis the
relative MAPPIT signal of every wild type is higher than 0.45
(Figure 4B, C, D, E). All mutants with a relative MAPPIT signal
#0.65 for the Vif, Apobec3G or Gagpol preys plus.0.5 for the
SH2-Bb prey were sequenced. The resulting single amino acid
substitutions are listed in tables S2 and S3 in supporting
information. A relative MAPPIT signal below 0.45 strongly
suggests that the mutant affects the interaction, a relative MAPPIT
signal between 0.45 and 0.65 may indicate a weaker effect on the
interaction. The mutations and their relative MAPPIT signal with
the three interactions partners were mapped on a homology model
for the N-terminal domain and on the crystal structure of the C-
terminal domain. Surface areas where mutations with low relative
MAPPIT signals cluster, indicate possible interaction surfaces.
Selected mutations in these areas were retested in additional
MAPPIT assays to confirm the effect of the mutation.
Surprisingly, the relative MAPPIT signal of the SH2-Bb prey
for wild type Apobec3G is lower than for many of the Apobec3G
bait mutants including the W127A mutant. Although this suggests
a lower expression level for wild type Apobec3G, Western blot
analysis confirms the proper expression of the wild type and
mutant Apobec3G baits (figure S3). The luciferase values after Epo
stimulation are very similar for wild type and mutant baits with the
SH2-Bb prey. (figure S4). The lower fold induction for the wild
type bait is rather caused by an unusually high luciferase reporter
activity of the unstimulated wild type bait. This may mean that
homodimerization of Apobec3G in the wild type bait is able to
partially activate JAK2 of the bait receptor from the cytosolic side,
leading to luciferase reporter activity with the SH2-Bb prey in the
Figure 1. Effect of site-directed mutations in the N-terminal CDA domain of Apobec3G on the interactions with Gagpol and Gag. A:
Effect of mutations on the Apobec3G-Gag interaction. Interactions between the Gag prey and the different mutant Apobec3G baits were determined
via MAPPIT. The data are expressed as fold induction of luciferase activity after stimulation with Epo. All mutations that disrupt the Apobec3G-Gagpol
interaction (Red/Orange in panel C) also disrupt the Apobec3G-Gag interaction. B &C: The effects on the Apobec3G-Apobec3G (B) and Apobec3G-
Gagpol (C) interaction were determined via MAPPIT. The residues of the head-to-head interface are directed towards the viewer. B: Effect of
mutations on the Apobec3G-Apobec3G interaction (47). C: Effect of mutations on the Apobec3G-Gagpol interaction. The colors in A and B indicate
the relative MAPPIT signal of the Apobec3G bait mutants, compared to wild type. Color codes: Red: ,25% of WT, orange: ,50% of WT, black: .50%
of WT (no strong effect). Mutations that disrupt the Apobec3G-Apobec3G interaction (Red/Orange) also disrupt the Apobec3G-Gagpol interaction.
doi:10.1371/journal.pone.0044143.g001
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absence of Epo ligand. Bait mutations that affect the Apobec3G
homodimerization do not show this effect.
Random mutagenesis of the N-terminal CDA domain of
Apobec3G
In the N-terminal domain, 81 different single amino acid
substitutions were identified that affect the MAPPIT signal with
one or more of the preys (Table S2 in supporting information).
The 81 mutations correspond to 58 residues in the N-terminal
domain. All these mutations disturbed the interaction with both
Vif, Apobec3G and Gagpol, in line with our previous observation
from the mutagenesis analysis of the head-to-head interface. None
of the single amino acid substitutions had a specific effect on one of
the three interactions. Only a combined A51V/P129S mutation
specifically affected the Apobec3G-Vif interaction, which is
probably due to the mutation of residue P129. Figure 5 shows a
map of the mutations on a model for the Apobec3G N-terminal
domain. Half of the mutations occur at 28 buried residues and
probably influence the structure, folding or stability of the N-
terminal domain. 30 mutated residues are surface exposed (.20%
RSA).
The surface exposed residues that strongly affected the three
interactions were all located in the predicted head-to-head
interface for Apobec3G homodimerization and corresponded
with those obtained previously in the site-directed mutagenesis
study of the Apobec3G-Vif, Apobec3G-Apobec3G [10] and
Apobec3G-Gag interactions (Table 1, Figure 1, Figure 5). This
shows that the random mutagenesis MAPPIT approach is very
well able to detect the interface areas of this protein-protein
interaction.
Several mutations in Apobec3G that weakly affected the three
interactions cluster in a region at the surface of the Apobec3G N-
Figure 2. Importance of the N- and C-terminal domain of Apobec3G for the interaction with Apobec3G, Vif, Gag and Gagpol
determined. A&B: Apobec3G, its N-terminal domain or its C-terminal domain were coupled to a V5-tagged MAPPIT bait receptor. Via MAPPIT, their
interactions were determined with preys for full-length Apobec3G, Vif, Gagpol and Gag. The data are expressed as fold induction of luciferase activity
after stimulation with Epo. C: Expression of the baits in panel A and B was determined via Western blot using an anti-V5 tag antibody. All baits are
properly expressed.
doi:10.1371/journal.pone.0044143.g002
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terminal domain containing a helices 2, 3 and 4. In a dimer model
for the Apobec3G N-terminal domain, these regions are juxta-
posed, and the mutations coincide with a region with a high RNA
binding propensity (Figure 6). This second region may therefore
form the RNA binding site of Apobec3G.
As the crystal structure of Apobec2 revealed that two Apobec2
molecules dimerize via pairing of the b2 strands, the b2 strand of
the Apobec3G N-terminal domain was predicted to interact with
the b2 strand of the C-terminal domain [51]. The lack of
disruptive mutations in this area of the Apobec3G N-terminal
domain suggests that the described interaction is not important for
the tested interactions of Apobec3G.
Random mutagenesis of the C-terminal CDA domain of
Apobec3G
68 different single amino acid substitutions in the C-terminal
domain of Apobec3G affected at least one of the tested
interactions and corresponded to 56 different residues in the C-
terminal domain (Table S3 in supporting information). 27 mutated
residues were in the core of the protein (,20% RSA) and 29 are
surface residues (.20% RSA). The effect of most mutations on the
three interactions strongly coincided (Figure 7), as for mutations in
the N-terminal domain. No disruptive mutations were found at the
surface exposed residues of the a1-b1 and b4-a4 loops and the a6
helix of the C-terminal domain, indicating that a tail-to-tail type
interaction of the C-terminal domains does not play a role in the
Apobec3G interactions detected by our MAPPIT assays. In
contrast, random mutations of Y222, Q237, R238, R239, G240,
F241, V265, W269, K270 and a site-directed F268N mutation in
the center of the b2 strand and the a2 helix affected the interaction
with the Gagpol prey (Figure 7D and table S3 in supporting
information). We showed a similar disruptive effect of F268N and
W269S mutations on the interaction with the Gag prey
(Figure 1A), confirming that this zone around the b2 strand and
the a2 helix plays a role in the interaction with Gag. Mutations in
this region also slightly affected the interaction with the Vif prey,
suggesting that this region is also involved in the interaction with
Vif (Figure 7B).
We tested the effect of combined mutations in the a2-b2 area of
the Apobec3G bait on the interactions with the Vif, Gag, Gagpol
and Apobec3G baits (Figure S5 in supporting information). The
combined mutations drastically affect all interactions, including
the interaction with the Apobec3G prey. This suggests that the a2-
b2 area may also play a role in the Apobec3G-Apobec3G
interaction. All these bait mutants seem to be properly expressed,
Table 1. Overview of the effect of mutations in the
Apobec3G MAPPIT bait on the interaction with the Gagpol
prey.
Gagpol %WT stdev
V9A 101 14
R11S 83 17
M12A 25* 13
R14S 106 46
Y19A 36* 18
YNFY19-22ANFA 2* 2
N20A 71 16
Y22A 15* 4
R24S 19* 10
LS27-28AA 48* 20
RR29-30SS 2* 1
N31S 78 8
T32Q 118 44
T32D 111 31
T32E 81 15
W34A 50 15
R55A 64 28
K63E 104 51
W94A 4* 3
TK98-99AS 79 20
TK98-99AD 74 12
K99D 96 24
R102A 1* 1
RD102-103SS 63 16
RD102-103EK 85 50
TF106-107AA 94 20
E110S 80 14
E110K 84 25
D111K 9* 8
R122S 1* 0
L123A 2* 1
Y124A 61 20
YY124-125SS 1* 1
YFW125-127DY 1* 1
W127A 1* 1
D128K 98 23
D128Q 71 8
D128H 60 16
P129A 70 23
D130A 103 58
QE132-133AA 80 25
R136A 48* 29
S137A 127 37
F157A 4* 3
YS166-167AA 80 19
F172A 3* 2
W175A 2* 1
Table 1. Cont.
Gagpol %WT stdev
Y181A 3* 1
L184A 110 21
MAPPIT luciferase fold inductions for each mutant are expressed as percentage
of wild type Apobec3G bait. The averages of several independent MAPPIT
experiments and standard deviation (SD) are shown. Strongly decreased values
that are significantly different from the WT in a paired t-test are indicated by an
asterisk. HEK293T cells were transiently co-transfected with plasmids encoding
the chimeric Apobec3G WT or mutant Apobec3G bait constructs and Gagpol
prey constructs, combined with the pXP2d2-rPAP1-luci reporter. The
transfected cells were either stimulated for 24 h with Epo or were left
untreated. Luciferase measurements were performed in triplicate. Data are
expressed as a percentage of the WT fold inductions (Epo-stimulated/
unstimulated).
doi:10.1371/journal.pone.0044143.t001
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Figure 3. Method for the identification of randommutants that disrupt a protein-protein interaction based onMAPPIT. 1: A fragment
of the MAPPIT bait is randomly mutated via GenemorphH II PCR. 2: The mutated PCR fragments are ligated into the MAPPIT bait vector and the
resulting plasmid mutant pool is used to transform E. coli. 3: Plasmid DNA from the resulting colonies is prepared via automated 96-well DNA
miniprep. Each 96-well miniprep plate contains DNA from colonies of 72 mutants, 12 wild types and 12 negative controls. The DNA concentration in
all DNA samples is normalized to the same concentration. The resulting DNA is used to transfect HEK293T cells via an automated procedure using
liquid handling robots. 4: Each bait is co-transfected separately with four different MAPPIT preys and the luciferase reporter. Each bait/prey mixture is
used to transfect 8 wells of a 384-well plate with Hek293T cells. One 96-well MAPPIT bait miniprep plate in combination with four MAPPIT preys thus
leads to 8 transfected 384 well plates. Each transfected 384 well plate contains a single MAPPIT prey in combination with 6 wild type baits, 6 negative
control baits and 36 random bait mutants. 5: From each transfected bait/prey mixture, four wells are stimulated with Epo, the remaining four wells
Random Mutagenesis MAPPIT of Apobec3G
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as tested via the SH2-Bb prey. The MAPPIT signal for the mutant
baits with the SH2-Bb prey is much higher than for the wild type
bait, in line with our observations for mutations that disrupt the
Apobec3G-Apobec3G interaction.
We confirmed the inhibitory effect of a F268N+K270E
mutation on the Apobec3G-Vif and Apobec3G-Gag interaction
in co-immunoprecipitation experiments (figure S6). However, the
F268N+K270E mutant can be degraded by Vif like wild type
Apobec3G when the mutant Apobec3G and Vif are co-expressed
(data not shown).
F268 is found close to D264 and C261 in the a2 helix. D264
and C261 form an intermolecular Zn2+ bridge with H248 and
H250 of another Apobec3G C-terminal domain in the crystal
structure. A role for this zinc mediated intermolecular interaction
in oligomerization of Apobec3G was proposed [46]. We therefore
tested the effects of mutations of C261 and H248 on the
interaction of the Apobec3G bait with the Gag and Gagpol preys
(Figure S5 in supporting information). While the C261A mutation
had a slight effect, the H248A mutation had no significant effect
are not stimulated. After overnight Epo stimulation, the luciferase activity is determined via a luminescence reader. The MAPPIT signal is calculated by
dividing the signal of the four stimulated wells by the signal of the four unstimulated wells.
doi:10.1371/journal.pone.0044143.g003
Figure 4. Proof of principle and variation of wild type in the random mutagenesis experiments. A: As proof of principle, 48 different
colonies of the WT and W127A Apobec3G bait were picked and their DNA was miniprepped. These constructs were transiently transfected in
Hek293T cells in 384-well plates in combination with plasmids encoding the Vif prey and the pXP2d2-rPAP1-luciferase reporter. The transfected cells
were either stimulated for 24 h with Epo or left untreated. Luciferase measurements were performed in quadruplicate. Data are presented as fold
inductions of luciferase measurements. The method allows a clear discrimination between all WT and the W127A mutants. B,C,D,E: histograms of the
relative MAPPIT signal of all wild type Apobec3G baits with the four preys in our random mutagenesis experiments. The relative MAPPIT signal of
each wild type was calculated as described in the materials and methods section. The histograms of the relative MAPPIT signal of the wild types gives
an estimate of the variation of the WT signal in our mutant screens. The relative MAPPIT signal is always higher than 0.45.
doi:10.1371/journal.pone.0044143.g004
Random Mutagenesis MAPPIT of Apobec3G
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on the tested interactions, indicating that the Zn2+ bridge is
probably not involved in the interaction with Gag and Gagpol.
Discussion
By combining error prone PCR, automated 96-well DNA
minipreparation, automated 384-well transfections and MAPPIT,
we developed a strategy to screen for random mutations that
disrupt protein-protein interactions in intact living cells. Using this
strategy, 149 single amino acid substitutions that affected
interactions of Apobec3G were identified. The random mutagen-
esis MAPPIT approach allowed the detection of the previously
identified head-to-head interface in the CD1 domain as the most
prominent zone for Apobec3G-Apobec3G interaction. This
demonstrates that our random mutagenesis approach is able to
detect putative interaction interfaces in a way that is not biased by
a priori assumptions or models. Besides the known head-to-head
interface, the study suggests a new interface that may be involved
in RNA-mediated dimerization in the N-terminal domain.
Moreover, we defined a putative interface for Gag and Vif
binding in the C-terminal domain.
In the random mutagenesis MAPPIT approach, the interaction
surfaces of a bait protein with 4 different interacting preys can be
analyzed in parallel in the transfection experiment. After
determining the best conditions for error prone PCR, the use of
robotics permits mapping of the interactions of a protein with
different interaction partners in a few weeks. As the method can be
applied to all protein interactions that can be detected via
MAPPIT with a sufficient signal and signal/background ratio, we
estimate that up to 35% of the human protein-protein interactions
can be analyzed. As MAPPIT is used to validate the interaction
pairs obtained from yeast two-hybrid screens [57,58,59,60,61] and
an array-format MAPPIT was designed to screen for interactors of
a MAPPIT bait in a prey collection of 10.000 preys [62], an
increasing number of protein-protein interactions are validated or
detected via MAPPIT. The mode of interaction of these protein-
protein interactions can now directly be tested via the random
mutagenesis method. For example, we identified more than 100
mutations in the Toll-like receptor 4 (TLR4) adapter protein
TIRAP/Mal that disrupt its interaction with TLR4 and/or
MyD88 (Bovijn et al., unpublished results). Similarly, the strategy
was successfully used to detect mutations in the ring finger protein
RNF41 that specifically affect its interaction with new interaction
Figure 5. Position and effect of random mutations in the Apobec3G N-terminal CDA domain bait on MAPPIT interaction with a Vif,
Apobec3G or Gagpol prey. The residues of the head-to-head interface are directed towards the viewer. The effect of the mutation is indicated via
a color scale from black to red, as indicated below the models. Color codes: black: no mutation at this position or 100% of WT (no effect of the
mutation), Red: 0% of WT. The relative MAPPIT signal (expressed as % of Wild Type) is shown below the mutation indicator. A: Effect of mutations on
the Apobec3G-Vif interaction. B: Effect of mutations on the Apobec3G-Apobec3G interaction. C: Effect of mutations on the Apobec3G-Gagpol
interaction.
doi:10.1371/journal.pone.0044143.g005
Figure 6. Position and effect of random mutations in the
Apobec3G N-terminal CDA domain, modeled as a head-to-
head dimer. A: The effect of mutations on the Apobec3G-Apobec3G
interaction is indicated via a color scale from black to red, as in figure 5.
Color codes: black: no mutation at this position or 100% of WT (no
effect of the mutation), red: 0% of wild type. For each mutation, the
relative MAPPIT signals (expressed as % of Wild Type) for interaction
with the three preys are shown below the mutation indicator. From top
to bottom, the numbers indicate the relative MAPPIT signal for
interaction with the Vif prey, Apobec3G prey and the Gagpol prey.
Mutations at the surface of the Apobec3G N-terminal CDA domain
containing a helices 2, 3 and 4 are shown. In the dimer model, these
regions are juxtaposed. B: These mutations coincide with a region with
a high RNA binding propensity. The RNA binding propensity is shown
by color code: blue: high RNA binding propensity, red: low RNA binding
propensity. The putative RNA binding surface is indicated by a dashed
green line.
doi:10.1371/journal.pone.0044143.g006
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partners (Masschaele et al., unpublished results). In both studies,
the effect of the mutations was confirmed via orthogonal
interaction assays and activity tests.
To our knowledge, this is the first published strategy that
combines random mutagenesis with a broadly applicable method
to detect protein-protein interactions in living human cells. Other
mutagenesis strategies for identification of interaction interfaces
combine random mutagenesis with yeast two-hybrid, ribosome
display or phage display [63,64,65,66,67]. Unlike these methods,
MAPPIT takes place in the cytoplasm of an intact living human
cell. This can offer an advantage for proteins that require post-
translational modifications, such as phosphorylation, for their
interaction. Via heteromeric MAPPIT, it is even possible to bring
a modifying enzyme into proximity of the bait to promote its
interaction with a prey [68]. In heteromeric MAPPIT, the bait
protein and its modifying enzyme are coupled to two separate
receptor chains with the extracellular part of the a- or b- chain of
the GM-CSF receptor. Stimulation with GM-CSF brings the
modifying enzyme and the bait in close proximity, while
interaction of the modified bait with a MAPPIT prey is detected
as in the regular MAPPIT setup.
In our currently presented method, we used degenerated PCR
via Mutazyme II or random mutagenesis, as it allows a low
mutation frequency necessary to obtain single point mutations
[69]. Moreover, it allows all types of transitions and transversions
and shows a reasonably balanced distribution of mutations among
the different codons [69,70]. This reduces the risk of an
unbalanced distribution of mutations along the sequence, which
could bias our analysis.The Mutazyme II allows a good control of
the number of mutations by varying the number of PCR cycles
and the amount of input DNA. However, the exact conditions
probably differ for different proteins and need to be optimized
before the MAPPIT analysis.
Many different methods for the introduction of random
mutations have been described and most methods are probably
compatible with the method presented in this paper. For example,
the introduction of mutations via degenerated primers or gene
synthesis can allow the introduction of random mutations at
specific sites, and increase the number of single amino acid
substitutions [64,71]. Interestingly, scanning mutagenesis methods
via mu transposase variants allow the random integration, deletion
or replacements of single or multiple codons by one or more
Figure 7. Position and effect of random mutations in the Apobec3G C-terminal CDA domain bait on MAPPIT interaction with a Vif,
Apobec3G or Gagpol prey. The residues of the a2 and b2 region are directed towards the viewer. A: Ribbon model in the same orientation as in
panels B2D. B: Effect of mutations on the Apobec3G-Vif interaction. C: Effect of mutations on the Apobec3G-Apobec3G interaction. D: Effect of
mutations on the Apobec3G-Gagpol interaction. As in figure 5 and 6, the effect of the mutations in panel B2C is indicated via a color scale from black
to red. Color codes: black: no mutation at this position or 100% of WT (no effect of the mutation), red: 0% of WT. The relative MAPPIT signal
(expressed as % of Wild Type) is shown below the mutation indicator.
doi:10.1371/journal.pone.0044143.g007
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specific codons, allowing for example a random replacement of
amino acids by a specific amino acid type [72274].
For the development of the random mutagenesis strategy based
on MAPPIT, dimerization of Apobec3G and its interaction with
Vif and Gag were used as targets. In the absence of a structure of
Vif or of the full-length Apobec3G protein, several molecular
aspects of the interplay between Apobec3G and Vif remain
unclear. In a previous study, the importance of a predicted head-
to-head interface in the N-terminal domain was tested via site
directed mutagenesis and MAPPIT [10]. The study confirmed the
importance of this interface for Apobec3G-Apobec3G interaction,
but also demonstrated that the interface is required for Vif
binding. The current study shows that the head-to-head interface
of the N-terminal domain is also important for binding to Gag.
This correlates well with previous studies that showed the
importance of the N-terminal Apobec3G domain for the high
affinity interaction with Vif and the RNA-mediated interaction
with Gag [19,36,37]. The C-terminal domain of Apobec3G is the
catalytic deaminase domain and is the target of polyubiquitination
via Vif [19,35,75]. MAPPIT analysis indicates that the C-terminal
domain of Apobec3G is also important for interaction with
Apobec3G, Vif and Gag. We therefore tried to identify which
regions in the N- and C-terminal domain of Apobec3G are
involved in the different interactions via random mutagenesis.
A surprising outcome of the random mutagenesis MAPPIT
analysis is that no single amino acid substitutions were found that
specifically affect only one of the three tested interactions of
Apobec3G. A possible explanation for that is that specific binding
sites were missed because the coverage of our mutagenesis analysis
was too low. However, several arguments argue against this. In the
site-directed mutagenesis analysis of the N-terminal head-to-head
interface, we found that mutations of 17 residues affected the
interaction with Vif, Apobec3G [10] or Gag by more than 50%.
The random mutagenesis screen detected 12 of these residues,
suggesting 70% coverage. This coverage goes together with some
redundancy: 47 of the 114 mutated residues discovered in the
screen are found multiple times, often with different substitutions.
In the ongoing random mutagenesis analyses of Mal and RNF41,
we do find multiple mutations that specifically affect one of the
interactions without affecting the other interactions (unpublished
results), showing that our strategy is capable of finding specific
interaction interfaces.
Out of 149 different single amino acid substitution Apobec3G
mutants and an estimated 200 mutants with multiple amino acid
substitutions, only one mutant had a very specific effect on the
Apobec3G-Vif interaction: a combined A51V/P129S mutation.
This suggests that the number of single amino acid substitutions in
Apobec3G that can specifically affect the Apobec3G-Vif interac-
tion is possibly limited to a few residues around D128 and P129. In
the previous study, we reported that D128A, P129A, T32Q and
K99D mutations specifically affect the interaction with Vif [10].
These residues cluster in a small area at the edge of the Apobec3G
interface, which may be part of a Vif binding site. Mutating D128
to a lysine, which is the amino acid found at the corresponding
position in African green monkeys, disturbs the interaction of
human Apobec3G with HIV-1 Vif resulting in resistance to HIV-1
Vif. On the other hand, this Apobec3G D128K mutant is sensitive
to African green monkey SIV Vif [76,77,78,79]. The specificity of
the effect of a mutation in the D128/P129 area depends on the
type of substitution, as a D128G mutation detected in our screen
affected the interaction with the three preys, while a site-directed
D128K mutation specifically affected the interaction with the Vif
prey. This again supports the view that the Apobec3G dimeriza-
tion site is very close to the Vif binding site. As most mutations that
affect Apobec3G dimerization in our MAPPIT assay also affect
Vif binding, Vif may bind to an Apobec3G dimer, although we
cannot exclude that the Vif binding site simply strongly overlaps
with the Apobec3G dimerization site. The interaction of
Apobec3G mutants with Gag and Gagpol shows a similar pattern:
all mutants that strongly affect the Apobec3G-Apobec3G interac-
tion in MAPPIT affect the Apobec3G-Gagpol interaction.
Apobec3G dimerization requires RNA, as RNAse treatment
abolishes the Apobec3G-Apobec3G interaction [10]. In our head-
to-head dimer model of the N-terminal domain, many positively
charged residues were found in an extended symmetrical surface
formed by a helices 2, 3 and 4 of both monomers. In this surface,
we found a strong clustering of residues with a high RNA binding
propensity, suggesting that this surface is the RNA binding site.
This RNA binding site overlaps with, but seems to extend beyond
the positively charged pocket in the model of Huthoff et al., which
was shown to play a role in association with cellular RNA [51].
Binding of RNA to this putative RNA binding site may be
required to overcome the repulsive electrostatic force between the
positively charged N-terminal domains. Mutations in the RNA
binding site disrupt the interactions of Apobec3G with Apobec3G,
Vif and Gag.
Apobec3G forms dimers, tetramers and oligomers. The crystal
structure of the C-terminal domain of Apobec3G reveals several
intermolecular contacts. The largest interaction interface (901 A˚2)
corresponds roughly to the head-to-head interface found in
Apobec2, although the contacts are quite different. A W211A/
R213A/R374E mutation in this interface abolishes the Apobec3G
deaminase activity and its antiviral effect [46]. Mutations in this
tail-to-tail interface of the C-terminal domain interfere with
Apobec3G oligomerization [80]. This leads to a model where
Apobec3G forms dimers via the head-to-head interface of the N-
terminal domain and further oligomerizes via tail-to-tail interac-
tions between C-terminal domains, as predicted by Wedekind et
al. (48). The random mutagenesis screen did not detect disruptive
mutants in the predicted tail-to-tail interface of the C-terminal
domain. However, it is possible that the MAPPIT assay cannot
detect mutations that affect oligomerization of the Apobec3G bait.
A second smaller interface (604 A˚2) in the crystal structure of
the Apobec3G C-terminal domain contains residues of the b2
strand and the a2 helix. This interface contains two zinc ion
binding sites coordinated by H248, H250, C261 and D264. A
H248A/H250A mutation does not interfere with Apobec3G
oligomerization in vivo [81], and the significance of this interface
for the function Apobec3G is unclear. Apobec3G binding to Vif
and Gag is affected by mutations in the b2 strand and the a2 helix
of the C-terminal domain of Apobec3G. However, H248A and
C261A hardly affect these interactions, indicating that the role of
the b2 strand and the a2 helix in interactions of Apobec3G is not
related to the proposed zinc-mediated Apobec3G oligomerization
(Figure S5 in supporting information).
In the crystal structure, Apobec2 dimerizes via direct interac-
tions between the b2 strands. A similar dimerization was predicted
between the N-and C-terminal domain of Apobec3G, in a model
where the b2 strand of the N-terminal domain interacts with the
b2 strand of the C-terminal domain. The discontinuous b2 strand
in the different structures of the C-terminal catalytic domain seems
to prohibit this mode of dimerization [44,45,46,47,48]. However,
molecular dynamics simulations predict that the b2 strand of the
C-terminal domain may be able to adopt a more extended b
strand conformation to allow interactions between two b2 strands
[51]. Our extensive random mutagenesis analysis does not support
dimerization between the b2 strand of the C- and N-terminal
domains. Sharply in contrast with the effect of mutations in the b2
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strand area of the C-terminal domain, we did not identify any
mutations in the b2 strand area of the N-terminal domain that
affect Apobec3G dimerization, or its interaction with Gag or Vif.
This argues against an interaction between the b2 strand areas of
the N- and C-terminal domain.
Our MAPPIT assays are set up to detect clusters of mutations
that affect the interaction in this assay, in order to delineate
possible interaction interfaces. However, the effect of a mutation in
our (and other) interaction assays should not be extrapolated
automatically to an effect of the mutation on biological activity. A
F268N+K270E mutation in Apobec3G affects the interaction with
a Vif prey in MAPPIT and in co-immunoprecipitation. The same
mutation had no effect on degradation of Apobec3G by Vif.
Different assays may have different sensitivities towards a
mutation, as illustrated by several examples of differing results in
studies of Apobec3G. Huthoff et al. showed that mutations of
Apopbec3G Y124 toW127 do not affect degradation by Vif [55].
Our MAPPIT assay shows a strong effect of these mutations on the
Apobec3G-Vif bait-prey interaction, suggesting that the Apo-
bec3G dimer interface may nevertheless play a role in interaction
with Vif [10]. In line with this, a more drastic YFW125-127DY
mutation in the dimer interface does affect the interaction with Vif
in another study [37]. In another example, our MAPPIT data
support the finding of Huthoff et al. that W127A and Y124A
mutations affect Apobec3G dimerization [51]. In contrast, Khan
et al. report that these mutations do not affect Apobec3G-
Apobec3G interaction in their assays [82].
In summary, we developed a new strategy to detect random
mutations that disrupt a protein-protein interaction in intact
human cells. The strategy was able to detect the head-to-head
interface for Apobec3G dimerization and demonstrates its role in
interaction with Vif and Gag. Moreover, a new area in the C-
terminal domain that is important for the interaction of Apobec3G
with Vif and Gag was detected. Our MAPPIT analyses thus
identified four potential interaction surfaces in Apobec3G: a head-
to-head interface, a Vif binding site and an RNA binding site in
the N-terminal domain, and a binding site that is involved in
binding of Vif and Gag in the C-terminal domain. The random
mutagenesis MAPPIT strategy is broadly applicable and offers the
advantage that the effect of many mutations of a protein on
interaction with multiple interaction partners can be analyzed in
parallel. Our approach thus forms a new tool that can help to gain
insight in the structure of protein complexes or identify interesting
mutants for functional studies.
Materials and Methods
Bait, prey and reporter constructs
All constructs used in this report were generated by standard
PCR- or restriction based cloning procedures and used primers are
listed in table S1 in supporting infomation. Generation of the basic
MAPPIT bait receptor plasmid, pCEL, was described elsewhere
[9,83]. This pcDNA5FRT-derived pCEL vector contains the
extracellular part of the erythropoietin receptor (EpoR) and the
transmembrane and intracellular domain of the leptin receptor
(LR) with the tyrosines in the intracellular domain mutated to
phenylalanine. Generation of the bait construct pCEL-Apobec3G
and the mutant Apobec3G baits represented in table 1 were as
previously reported [10]. pCEL-Apobec3G-GFP, used for the
random mutagenesis study, contains Apobec3G with a C-terminal
eGFP-tag and was obtained in four steps: the NotI-site and
stopcodon of pCEL-Apobec3G were replaced by a StuI-site via
mutagenesis PCR with the QuickChangeH II Site-Directed
Mutagenesis Kit (Agilent Technologies) using primer pair 1. This
allowed in frame ligation of eGFP to the C-terminus of Apobec3G
after StuI-EcoRI-digestion. A BstBI-site was inserted in the
Apobec3G sequence using primer pair 2 whereas the SspI-site in
the vector was removed with primer pair 3. The resulting
construct is further referred to as pCEL-Apobec3G-GFP. pCEL-
Apobec3G W127A-GFP was acquired via mutagenesis of pCEL-
Apobec3G-GFP with primer pair 4. The pCEL-Apobec3G N-ter
construct was generated via the introduction of a stopcodon after
the N-terminal domain of Apobec3G in the pCEL-Apobec3G-
GFP construct via primer pair 5. This mutagenesis PCR also
introduced an extra SacI-site in pCEL-Apobec3G-GFP which
allowed the excision of the N-terminal domain to obtain a bait
construct with only the C-terminal domain as bait, pCEL-
Apobec3G C-ter-GFP. A stopcodon between the Apobec3G
domain and GFP was introduced via primer pair 6. Five mutant
Apobec3G bait constructs were generated via site directed
mutagenesis with the primer pairs 7211 represented in table S1
in supporting information.
The basic MAPPIT prey construct, pMG2, was generated in
the pMET7 vector and contains a part of the gp130 chain in
duplicate as previously described [68]. pMG2-Apobec3G, pMG2-
VifoptSLQ [10], pMG2-SH2-Bb [84] and the STAT3 inducible
pXP2d2-rPAP1-luciferase reporter [85] were obtained as de-
scribed before. pMG2-Gagpol was created by inserting Gagpol
from pGA-gagpol(160) (Kind gift of Tibotec) in pMG2 after
EcoRI-NotI-digestion. pMG2-Gag was obtained via amplification
of Gag using primer pair 12 on pNL4-3 (Kind gift of Dr. C.
Verhofstede) and ligation in pMG2 after EcoRI-XbaI-digestion. A
prey construct with the N-terminal domain of Apobec3G as prey
was generated via mutagenesis of pMG2-Apobec3G with primer
pair 13 introducing a stopcodon after the N-terminal domain of
Apobec3G as well as an extra EcoRI-site. pMG2-Apobec3G-Cter
was constructed via EcoRI-digestion of pMG2-Apobec3G N-ter
stop and self ligation without the N-terminal domain. pMG2-SVT
contains amino acids 261–708 of SV40 large T antigen as prey in
the pMG2 vector, and was previously described [68].
Cell culture and transfection protocol in 6-well and 96-
well plates
HEK293T cells (293T/17 obtained from www.atcc.org) were
cultured in a 8% CO2 humidified atmosphere at 37uC and grown
in Dulbecco’s modified Eagle’s medium (Invitrogen) with 10%
fetal calf serum (Cambrex Corp.). The transfection procedure for
6-well plates was previously described [85]. For 96-well transfec-
tions, 10 000 cells were seeded in black 96-well plates. One day
later, the cells were transfected with the desired bait and prey
plasmid DNA in the presence of the luciferase reporter gene using
the calcium phosphate precipitation procedure. 8 wells were
transfected with the same bait/prey transfection mix. The day
after transfection, 4 of these wells were stimulated overnight with
10 ng/ml hEpo (Roche) or left untreated. Luciferase activity was
measured by chemiluminescence in a TopCount luminometer
(Canberra Packard) or an EnVision Multilabel Plate Reader
(PerkinElmer).
Western Blot analysis
Expression of the MAPPIT preys was detected using the M2
mouse monoclonal antibody against the FLAG-tag and a
fluorescent goat-anti mouse antibody (LI-COR IRDye 800CW)
with detection via the Odyssey imager (LI-COR). Expression of
the Apobec3G bait was detected using a rabbit anti-Apobec3G
antibody (Sigma prestige antibodies) and a goat anti-rabbit
peroxidase conjugate (Jackson Immunoresearch) with detection
of chemiluminescence (SuperSignal West Pico Chemiluminescent
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Substrate, Pierce) via autoradiography. V5-tagged MAPPIT baits
were detected using a mouse monoclonal anti-V5 tag monoclonal
antibody (Invitrogen) and anti-mouse peroxidase conjugate (KPL)
as described above.
Co-immunoprecipitation
HA-tagged Apobec3G was co-expressed with the MAPPIT prey
for VifOptLQ, Gag or SVT in HEK293T cells, by Calcium
phosphate transfection as described above. Two days after
transfection, cells were lysed with 50 mM Tris-HCl pH 7.5,
125 mM NaCl, 5% glycerol, 0.2% NP40 and Complete Protease
Inhibitor Cocktail without EDTA (Roche). The lysates were
cleared by centrifugation and incubated for 3 hours with 20 ml
monoclonal anti-flag M2 agarose beads (Sigma) to precipitate the
MAPPIT preys. The beads were washed four times with 1 ml lysis
buffer. The precipitated MAPPIT preys and co-immunoprecipi-
tated Apobec3G were released from the beads by incubation with
100 mg/ml synthetic FLAG peptide for 30 min at 37uC. After
centrifugation of the beads, co-immunoprecipitated Apobec3G in
the supernatant was detected by Western blot using rat anti-HA
monoclonal antibody 3F10 (Roche) and fluorescent goat anti-rat
antibody (LI-COR IRDye 800CW) with detection via the Odyssey
imager (LI-COR).
Random mutagenesis of the bait
Apobec3G from the pCEL-Apobec3G-GFP bait is randomly
mutated using the GeneMorphH II Random Mutagenesis Kit
(Agilent Technologies). The N-terminal part of Apobec3G (bp
12533) was mutated via error prone PCR of pCEL-Apobec3G-
GFP with primer pair 14 from which the forward primer contains
a SacI- and the reverse primer a SspI-recognition site. The total
amount of plasmid DNA added to the reaction was 200 ng and 15
PCR cycles were performed. After digestion with SacI and SspI,
the PCR product was introduced in the SacI-SspI opened pCEL-
Apobec3G-GFP vector. For the random mutagenesis PCR of the
C-terminal part (bp 52221152), forward primer 15 and reverse
primer 15 with respectively a BstBI- and StuI-site, were used. For
this reaction, the amount of start DNA was 1000 ng and the
number of cycles was 10. The resulting PCR fragments were
digested with BstBI and StuI and ligated in the BstBI-StuI opened
pCEL-Apobec3G-GFP vector. After transformation of the ran-
domly mutated Apobec3G bait plasmids in E. coli, 1152 different
colonies were picked for both mutagenesis reactions and these
2304 colonies were grown overnight in 2xYT medium in 32 96-
deepwell blocks. Row A2F of each deepwell block was inoculated
with 72 different mutant colonies, row G was inoculated with 12
different wild type pCEL-Apobec3G-GFP colonies, row H was
inoculated with 12 different pCEL-Apobec3G W127A-GFP
mutant colonies. Automated miniprep of these 32 deepwell blocks
was performed using the NucleospinH Robot-96 plasmid kit and a
Freedom EVO 100 platform (Tecan). The DNA concentration
was automatically measured using a Magellan UV spectropho-
tometer (Tecan) and diluted to 6 ng/ml.
Automated transfection protocol in 384-well plates and
MAPPIT analysis
One day before transfection, 3000 cells per well were seeded in
black 384-well plates. Cells were transfected overnight with 1.5 ng
bait plasmid, 6.5 ng prey plasmid and 4 ng of the pXP2d2-rPAP1-
luciferase reporter per well. Automated transfection via the
calcium phosphate precipitation procedure was executed by a
Freedom EVO 200 platform (Tecan). 8 wells were transfected with
the same bait/prey mixture. Thus, one 384-well plate contained
bait/prey mixtures of half of a 96-well bait DNA plate (36 mutant
Apobec3G baits, 6 wild type control baits and 6 negative control
baits) in combination with one prey. The day after transfection, 4
of the 8 wells were stimulated overnight with 10 ng/ml hEpo, the
other 4 wells were left unstimulated, so that all bait/prey
combinations were assayed in quadruplicate in both unstimulated
and ligand stimulated conditions. After another 24 h, luciferase
activity in cell lysates was measured using an EnSpire plate reader
(PerkinElmer).
Analysis of the random mutagenesis MAPPIT data
The MAPPIT signal was determined as fold induction of
luciferase activity upon Epo stimulation, by dividing the luciferase
activity of the 4 Epo stimulated wells by the luciferase activity of
the 4 unstimulated wells.The MAPPIT signal of each bait mutant
was compared with the MAPPIT signal of the six wild type baits
on the same 384-well plate to calculate a normalized MAPPIT
signal. The normalized MAPPIT signal is the result of the fold
induction of the mutant divided by the median of the fold
induction of the six wild types controls on that plate. The 384-well
transfections were repeated three times. For each mutant, we
calculated a relative MAPPIT signal. The relative MAPPIT signal
is the median of the normalized MAPPIT signals of a mutant in
three transfection experiments multiplied by 100. The relative
MAPPIT signal of a mutant is expressed as percentage of wild
type.
Thresholds were determined for the relative MAPPIT signal, as
described in the results section. Mutations that gave rise to a
relative MAPPIT signal above (SH2-Bb prey) or below (Vi-
foptSLQ, Gagpol or Apobec3G preys) these thresholds were
selected for sequencing of the Apobec3G mutant. Sequences were
determined on Applied Biosystems 3730XL DNA Analyzers
at the VIB Genetic Service Facility (http://www.
vibgeneticservicefacility.be/). The sequences were aligned to the
pCEL-Apobec3G-GFP protein sequence using NCBI BLASTx
[86]. The resulting protein alignments were concatenated and
realigned using MAFFT [87] and visualized with Jalview [88] to
identify amino acid substitutions.
Molecular modeling and visualization
The mutations that affected the relative MAPPIT signal were
mapped on the structure of the Apobec3G C-terminal domain
[45], or on a homology model of the Apobec3G N-terminal
domain [10]. The structures were visualized using UCSF chimera
[89] and the mutations were colored according to their relative
MAPPIT signal using the ‘render by attribute’ tool of UCSF
chimera. To identify possible RNA binding sites, all residues in
Apobec3G models were colored according to their statistical
potential for RNA binding as defined by Pe´rez-Cano and
Ferna´ndez-Recio [90]. The solvent accessibility of residues was
calculated via NACCESS (Hubbard,S.J. & Thornton, J.M. (1993),
‘NACCESS’, Computer Program, Department of Biochemistry
and Molecular Biology, University College London.’’), using a
probe radius of 1.4 A˚. The relative solvent accessibility (RSA) of
residues is calculated as the % accessibility compared to the
accessibility of that residue type in an extended ALA-x-ALA
tripeptide [91].
Supporting Information
Figure S1 MAPPIT principle. A MAPPIT bait construct is
composed a bait protein which is coupled to the C-terminus of a
chimeric receptor consisting of the extracellular domain of the
erythropoietin receptor (EpoR) and the transmembrane and
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intracellular part a leptin receptor that lacks STAT3 recruitment
sites. In the absence of an interacting prey, the bait is unable to
signal via STAT3. The prey protein is fused to a duplication of a
fragment of the gp130 receptor chain carrying tyrosine motifs that
recruit STAT3 after phosphorylation by JAK2. Interaction
between bait and prey in combination with stimulation with Epo
thus leads to functional complementation of JAK2-STAT3
signaling and induction of a luciferase reporter.
(TIF)
Figure S2 A Gag 1–377 prey does not interact with the
Apobec3G bait in MAPPIT. The interactions of an Apobec3G
bait with preys for full-length Gag and for Gag 1–377 is
determined via MAPPIT. The data are expressed as fold induction
of luciferase activity after stimulation with Epo. The SH2Bb prey
and SVT prey are used as a positive and negative control. The
MAPPIT signal for the Gag1–377 prey drops to the level of the
negative SVT prey control (dotted arrow).
(TIF)
Figure S3 Expression control of prey and bait proteins.
Western blot analysis of expression of the MAPPIT preys (A) and
of selected Apobec3G MAPPIT baits (B), as described in materials
and methods. The Apobec3G N-terminal domain is not detected
by the anti-Apobec3G antibody, which is directed against the
Apobec3G C-terminal domain. The Apobec3G H250A mutant is
not expressed, in line with the absence of a MAPPIT signal of this
mutant in the SH2-Bb assay (Figure S5 in supporting information).
(TIF)
Figure S4 Effect of mutations on the MAPPIT signal
with the SH-2Bb prey. The luciferase activity before and after
Epo stimulation with the SH2-Bb prey is compared for different
baits. This is compared to the MAPPIT interaction of these baits
with the Apobec3G prey. A: Luciferase activity after Epo
stimulation with the SH2-Bb prey. B: Luciferase activity without
Epo stimulation with the SH2-Bb prey. C: Fold induction of
luciferase activity with the SH2-Bb prey. D: Fold induction of
luciferase activity with the Apobec3G prey. All four baits show a
similar luciferase activity with the SH2-Bb prey after Epo
stimulation (A). Only the wild type Apobec3G bait and the
Q237K+R238C Apobec3G bait interact with the Apobec3G bait
(D). Both baits show a high luciferase activity with the SH2-Bb
prey when not stimulated (B), leading to a lower fold induction of
luciferase activity for these two baits with the SH2-Bb prey (C). In
contrast, the F268N+K270E mutant and the negative control bait
(receptor without bait) do not interact with Apobec3G (D). These
two baits have a low luciferase activity SH2-Bb prey without Epo
stimulation (B) and thus have a high fold induction of luciferase
activity after Epo stimulation (C). The capability of an Apobec3G
bait to interact with the Apobec3G prey seems to parallel its
capability to induce luciferase activity with the SH2-Bb prey in the
absence of Epo stimulation.
(TIF)
Figure S5 Effect of mutations in a putative zinc-binding
motif and of combined mutations in the C-terminal
domain. Interactions between different mutant Apobec3G baits
and different MAPPIT preys were determined via MAPPIT. The
data are expressed as fold induction of luciferase activity after
stimulation with Epo. H248A and C261A mutations have only
modest effects on any of the interactions. The H250A mutant
Apobec3G bait shows no MAPPIT signal with the SH2-Bb prey,
indicating that the bait is not expressed, which is in line with the
Western blot analysis (supporting figure S3). Combined mutations
(C261A+F268N, F268N+K270E, Q237K+F268N+K270E,
Q237K+R238C+F268N+K270E) in the b2 strand and a2 helix
strongly affect the interactions with the Vif, Apobec3G, Gagpol
and Gag preys.
(TIF)
Figure S6 Effect of the F268N+K270E mutation on co-
immunoprecipitation of Apobec3G with MAPPIT preys
for Gag and VifOptSLQ. HA-tagged Apobec3G or its
F268N+K270E mutant is co-expressed with the MAPPIT preys
for Gag and VifOptSLQ in HEK293T cells. After immunopre-
cipitation of the prey, with anti-FLAG agarose, the co-precipitated
HA-tagged Apobec3G is determined via Western Blot. The
asterisk indicates the HA-Apobec3G bands, the prey bands are
indicated with an arrowhead. A. The F268N+K270E mutant (left
panel, lane 2) co-immunoprecipitates less efficiently with the Gag
prey than Wild-type HA-Apobec3G (left panel, lane 1). B. The
F268N+K270E mutant (left panel, lane 3) co-immunoprecipitates
less efficiently with the VifOptSLA prey than Wild-type HA-
Apobec3G (left panel, lane 1).
(TIF)
Table S1 Primers used to obtain the described DNA
constructs.
(DOC)
Table S2 Random single-residue mutations identified
in the N-terminal CDA domain. Column 1 shows the
mutations. The relative solvent accessibility of the mutated residue
is shown in column 2. The relative MAPPIT signal (% of WT) of
the bait mutants for interaction with the Vif, Apobec3G,Gagpol
and SH2-Bb preys is given in columns 3–6.
(DOC)
Table S3 Random single-residue mutations identified
in the C-terminal CDA domain. Column 1 shows the
mutations. The relative solvent accessibility of the mutated residue
is shown in column 2. The relative MAPPIT signal (% of WT) of
the bait mutants for interaction with the Vif, Apobec3G,Gagpol
and SH2-Bb preys is given in columns 3–6.
(DOC)
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